SciELO - Scientific Electronic Library Online

 
vol.76 número4Tratamiento con tofacitinib en adolescentes con alopecia areataZika como causa de aborto espontáneo en zonas endémicas índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Boletín médico del Hospital Infantil de México

versión impresa ISSN 1665-1146

Resumen

REY-HELO, Elianneth; PEREZ-VELASQUEZ, Rubén D.  y  CORTES-ALVA, Deyanira. Agressive NK-cell leukemia in a pediatric patient. Bol. Med. Hosp. Infant. Mex. [online]. 2019, vol.76, n.4, pp.188-192.  Epub 13-Mar-2020. ISSN 1665-1146.  https://doi.org/10.24875/bmhim.19000089.

Background:

Natural killer (NK) cell neoplasms are rare and represent <5% of all lymphoid neoplasms. They involve different clinical entities, of which one is NK cell leukemia, a highly aggressive hematologic neoplasm with poor prognosis that presents in young men and is more frequently seen in Asian descent. Epstein-Barr virus (EBV) seems to be related to the pathogenesis.

Case report:

A male patient of 1 year and 7 months of age, who began his condition with anemic, febrile, infiltrative syndrome and hyperleukocytosis is described. Bone marrow aspirate showed L2 morphology blasts (96%), CD56 (80.87%) and terminal deoxynucleotidyl transferase (84.11%) immunophenotype. Bone marrow biopsy showed membranous CD2+, cytoplasmic CD3+ and membranous CD56+; serology positive to EBV. The patient received two different chemotherapy schemes based on methotrexate, ifosfamide, etoposide, dexamethasone and L-asparaginase, which resulted in partial remission. Currently, the patient lives with the disease.

Conclusions:

NK cells leukemia is rare in young adults, but even more in pediatric patients, for which it is very difficult to treat because only a few cases have been reported in the literature, the survival varies from weeks to months and the chances of treatment are limited. Recently, the usefulness of allogeneic bone marrow transplantation or umbilical cord cells has been demonstrated, achieving a 2-year survival. The therapeutic possibilities in these patients are under study. In the near future, we hope to achieve the complete remission of the disease and a 5-year survival.

Palabras llave : Leukemia; Pediatrics; Natural killer cells; Pancytopenia.

        · resumen en Español     · texto en Español     · Español ( pdf )